enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Editas Medicine - Wikipedia

   en.wikipedia.org/wiki/Editas_Medicine

   Editas Medicine was originally founded with the name "Gengine, Inc." in September 2013 by Feng Zhang of the Broad Institute, Jennifer Doudna of the University of California, Berkeley, [7] and George Church, David Liu, and J. Keith Joung of Harvard University, with funding from Third Rock Ventures, Polaris Partners and Flagship Ventures; the name was changed to the current "Editas Medicine" two ...

3. Editas (EDIT) Up More Than 100% in Past 3 Months: Here ... - AOL

   www.aol.com/news/editas-edit-more-100-past...

   Editas' (EDIT) lead candidate EDIT-101, that employs CRISPR gene editing to treat LCA10, holds potential. The company is also developing EDIT-301 for treating SCD. Editas (EDIT) Up More Than 100% ...

4. Editas Medicine Stock History: The Story Behind the ... - AOL

   www.aol.com/news/editas-medicine-stock-history...

   Here's the story behind the biotech stock that could be the best way to profit from the discovery of the century: CRISPR-Cas9 gene editing.

5. Google Patents - Wikipedia, the free encyclopedia

   en.wikipedia.org/wiki/Google_Patents

   Wikipedia entry for Google Patents.Google Patents is a search engine from Google that indexes patents and patent applications from the United States Patent and Trademark Office.

6. James Mullen (CEO) - Wikipedia

   en.wikipedia.org/wiki/James_Mullen_(CEO)

   James C. “Jim” Mullen (born ca. 1958) is an American business executive. He is the executive chairman at genome editing company Editas Medicine since 2018, where he also served as CEO between 2021 and 2022.

7. Editas Medicine Announces $50+ Million Monetization Financing ...

   lite.aol.com/tech/story/0022/20241003/9251178.htm

   CAMBRIDGE, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced the sale of certain future license fees and other payments owed to Editas Medicine under its Cas9 license agreement with Vertex Pharmaceuticals to a wholly-owned subsidiary of DRI Healthcare Trust (DRI) for an upfront cash payment of $57 million.

8. Editas Medicine Prepares to Make History With EDIT-101 - AOL

   www.aol.com/news/editas-medicine-prepares...

   After another solid quarter of progress, the genome-editing company looks forward to a phase 1/2 study for its revolutionary CRISPR medicine. Editas Medicine Prepares to Make History With EDIT-101 ...

9. Editas (EDIT) Focuses on Developing Gene Drug for Eye Disease

   www.aol.com/news/editas-edit-focuses-developing...

   Editas (EDIT) progresses well with the development of its lead candidate, EDIT-101, to treat LCA10, a rare genetic illness that causes blindness. Dependence on partners for revenues is a concern.